Clinical Trials Directory

Trials / Completed

CompletedNCT03705117

Open-label V565 Target Engagement Study

An Open-label Exploratory Study in Patient Volunteers With Ulcerative Colitis (UC), to Investigate Lamina Propria Presence and Evidence of Biological Effect of the Oral Domain Antibody V565

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
5 (actual)
Sponsor
VHsquared Ltd. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to confirm that V565 enters inflamed tissue, binds to TNF and reduces inflammation after oral dosing to patients with IBD.

Detailed description

Single-site, open-label study in up to 6 patients treated for up to 7 days with sigmoidoscopy and biopsies before and after treatment period to determine biological activity.

Conditions

Interventions

TypeNameDescription
BIOLOGICALV565Capsules for oral administration

Timeline

Start date
2017-05-23
Primary completion
2017-10-24
Completion
2017-10-24
First posted
2018-10-15
Last updated
2018-10-15

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03705117. Inclusion in this directory is not an endorsement.

Open-label V565 Target Engagement Study (NCT03705117) · Clinical Trials Directory